Market Place
Sourcing Support
Merck Sets Q4 And Full-Year 2024 Earnings Call For February 4
16 Jan 2025 //
BUSINESSWIRE
WuXi Biologics to sell Irish vaccine site to Merck for $500M
07 Jan 2025 //
ENDPTS
Merck to Participate in the 43rd Annual J.P. Morgan Conference
06 Jan 2025 //
BUSINESSWIRE
Merck wins UK approval for lung disease drug acquired in $11 B deal
01 Jan 2025 //
REUTERS
Merck to discontinue drug for bacterial infection
24 Dec 2024 //
REUTERS
Merck Closes Deal for LM-299 Anti-PD-1/VEGF Bispecific Antibody
20 Dec 2024 //
BUSINESSWIRE
Merck`s HIV combo treatment meets efficacy bar in Ph 3 trials
20 Dec 2024 //
FIERCE BIOTECH
Personalis Advances Strategy with Merck Investment, Moderna Deal
19 Dec 2024 //
BUSINESSWIRE
Merck signs up to $2 bln obesity drug deal with biotech Hansoh
19 Dec 2024 //
REUTERS
Merck discontinues development of 2 experimental cancer drugs
18 Dec 2024 //
REUTERS
Merck Announces FDA Acceptance of Clesrovimab BLA for RSV
17 Dec 2024 //
BUSINESSWIRE
Merck to acquire HUB Organoids to advance cell culture portfolio
17 Dec 2024 //
INDPHARMAPOST
Merck’s KEYTRUDA® Approved in China for NSCLC Neoadjuvant Treatment
16 Dec 2024 //
BUSINESSWIRE
Merck`s WELIREG® Gets EU Nod For VHL Tumors & Advanced RCC
13 Dec 2024 //
BUSINESSWIRE
Keros shares collapse on ‘unanticipated’ setback for lung drug
12 Dec 2024 //
BIOPHARMADIVE
LYNPARZA Demonstrates Prolonged Survival in Early Breast Cancer
11 Dec 2024 //
BUSINESSWIRE
Merck`s Biologic Keytruda Receives Suppl Approval in US
11 Dec 2024 //
FDA
Merck Manuals: What to Know About Listeria and Recent Recalls
11 Dec 2024 //
PR NEWSWIRE
Merck ADC RORs into phase 3 with 100% complete response rate
10 Dec 2024 //
PRESS RELEASE
Merck Announces Ph 3 KEYLYNK-001 Trial Success in Ovarian Cancer
09 Dec 2024 //
BUSINESSWIRE
Merck`s Zilovertamab Vedotin 100% Response in Phase 2 Lymphoma Trial
08 Dec 2024 //
BUSINESSWIRE
Merck & Ridgeback Start Ph 3 Study of LAGEVRIO™ for COVID-19
05 Dec 2024 //
BUSINESSWIRE
Former Merck USA President Joins Klotho Neurosciences
03 Dec 2024 //
GLOBENEWSWIRE
FDA Grants Breakthrough Status to Sac-TMT for EGFR NSCLC
03 Dec 2024 //
BUSINESSWIRE
Biopharma Takes on Deadly Brain Cancer After Decades of Failure
02 Dec 2024 //
BIOSPACE
Kelun-Biotech`s TROP2 ADC Approved in China for Advanced TNBC
27 Nov 2024 //
PR NEWSWIRE
Merck to Participate in Citi 2024 Global Healthcare Conference
26 Nov 2024 //
BUSINESSWIRE
Merck`s therapy for rare lung condition to help reduce risk of death
26 Nov 2024 //
REUTERS
Merck recommends rejection of TRC Capital’s “Mini-Tender” Offer
23 Nov 2024 //
INDPHARMAPOST
US FDA finds widely used asthma drug impacts the brain
23 Nov 2024 //
BIOSPACE
Surendralal Karsanbhai Elected to Merck Board of Directors
22 Nov 2024 //
BUSINESSWIRE
Merck To Participate In 7th Evercore ISI HealthCONx Conference
22 Nov 2024 //
BUSINESSWIRE
Merck Presents Promising Hematology Data at ASH Annual Meeting
21 Nov 2024 //
BUSINESSWIRE
Merck Sharp`s Biologic Keytruda Receives Suppl Approval in US
20 Nov 2024 //
FDA
Merck Foundation Announces $17M Cardiac Care Access Initiative
20 Nov 2024 //
ACCESSWIRE
Merck says Keytruda injection on par with approved IV version in trial
20 Nov 2024 //
FIERCE PHARMA
Merck Announces First-Quarter 2025 Dividend
19 Nov 2024 //
BUSINESSWIRE
Merck signs up to $3.3 billion cancer drug deal with LaNova
16 Nov 2024 //
REUTERS
Merck Receives CHMP Opinion for KEYTRUDA® in MPM
15 Nov 2024 //
BUSINESSWIRE
Merck joins ALA`s pulmonary arterial hypertension awareness push
14 Nov 2024 //
FIERCE PHARMA
Merck Licenses LM-299, Anti-PD-1/VEGF Bispecific Antibody
14 Nov 2024 //
BUSINESSWIRE
Merck to Participate in the Jefferies London Healthcare Conference
14 Nov 2024 //
BUSINESSWIRE
AZ, Merck`s Koselugo delivers trial win in adults with NF1
13 Nov 2024 //
FIERCE PHARMA
BMS, Merck, Amgen & more face near-term generic woes: Leerink
13 Nov 2024 //
FIERCE PHARMA
Merck, AstraZeneca Announce Phase 3 Win for Cancer Drug
12 Nov 2024 //
FIERCE BIOTECH
Merck to Present Gardasil 9 Supporting Gender-Neutral HPV Vaccine
12 Nov 2024 //
BUSINESSWIRE
Koselugo Shows Improve in NF1 Plexiform Neurofibromas in Ph 3 Trial
12 Nov 2024 //
BUSINESSWIRE
Merck to Participate in the UBS Global Healthcare Conference
06 Nov 2024 //
BUSINESSWIRE
Gardasil`s troubles in China haunt Merck in Q3
31 Oct 2024 //
FIERCE PHARMA
Merck Announces Third-Quarter 2024 Financial Results
31 Oct 2024 //
BUSINESSWIRE
Merck, Moderna Launch Phase 3 Trial for NSCLC Treatment
28 Oct 2024 //
BUSINESSWIRE
Sanofi isn`t sweating a potential RSV showdown with Merck
26 Oct 2024 //
FIERCE PHARMA
Merck’s KEYTRUDA® Receives New Approvals For Gynecologic Cancers
24 Oct 2024 //
BUSINESSWIRE
In boon for Pfizer and Merck, CDC panel backs expanded use of vaccines
24 Oct 2024 //
FIERCE PHARMA
Merck buys cancer therapy developer Modifi for up to $1.3 bln
24 Oct 2024 //
REUTERS
Merck-Gilead long-acting oral combo suppresses HIV for 48 weeks
22 Oct 2024 //
FIERCE BIOTECH
Merck`s RSV antibody for infants effective in reducing infections in study
18 Oct 2024 //
REUTERS
Merck’s Clesrovimab Significantly Reduces RSV In Infants
17 Oct 2024 //
BUSINESSWIRE
Merck’s Capvaxine Shows Response In Pneumococcal Disease
16 Oct 2024 //
BUSINESSWIRE
Exelixis And Merck Sign Clinical Development Collaboration
14 Oct 2024 //
BUSINESSWIRE
